scholarly article | Q13442814 |
P356 | DOI | 10.1158/1078-0432.CCR-17-1597 |
P8608 | Fatcat ID | release_svbkx3uu3jhaxkltdfmwwprc74 |
P932 | PMC publication ID | 5796858 |
P698 | PubMed publication ID | 28839110 |
P50 | author | Joseph D. Khoury | Q87653316 |
P2093 | author name string | Stanley R Hamilton | |
L Jeffrey Medeiros | |||
Neda Kalhor | |||
Russell Broaddus | |||
Meera Hameed | |||
Victor G Prieto | |||
Wei-Lien Wang | |||
P2860 | cites work | A landscape of driver mutations in melanoma | Q24603357 |
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 | ||
RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database | Q24813953 | ||
Molecular mechanisms underlying RB protein function | Q27003956 | ||
Targeting the RB-E2F pathway in breast cancer | Q28069626 | ||
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
Proposals for the classification of the myelodysplastic syndromes | Q28275931 | ||
Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study | Q30361978 | ||
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q33862786 | ||
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer | Q34027724 | ||
The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration | Q34167832 | ||
Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible | Q34574472 | ||
Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. | Q34786717 | ||
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints | Q34943776 | ||
Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. | Q35063442 | ||
Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing | Q35740291 | ||
Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing | Q35926060 | ||
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development | Q36193517 | ||
??? | Q26829177 | ||
Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. | Q36271327 | ||
Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas | Q37038863 | ||
Next-generation companion diagnostics: promises, challenges, and solutions | Q37190679 | ||
Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines | Q37659105 | ||
Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms | Q38065071 | ||
Principles of analytic validation of immunohistochemical assays: Guideline from the College of American Pathologists Pathology and Laboratory Quality Center | Q38197280 | ||
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network | Q38214265 | ||
Wilms tumor 1 (WT1) protein: Diagnostic utility in pediatric tumors | Q38424214 | ||
Principles of Analytic Validation of Clinical Immunohistochemistry Assays. | Q38603134 | ||
Treating cancer with selective CDK4/6 inhibitors | Q38794109 | ||
Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. | Q38833458 | ||
Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma | Q38848447 | ||
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. | Q39007646 | ||
The BCL2 E17 and SP66 antibodies discriminate 2 immunophenotypically and genetically distinct subgroups of conventionally BCL2-"negative" grade 1/2 follicular lymphomas. | Q51020727 | ||
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. | Q51692190 | ||
The evolving potential of companion diagnostics. | Q53064168 | ||
Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome. | Q53190261 | ||
PTEN/MMAC1 mutations in endometrial cancers. | Q53439663 | ||
High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice | Q57272679 | ||
Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors | Q57741132 | ||
Site and Tumor Type Predicts DNA Mismatch Repair Status in Cutaneous Sebaceous Neoplasia | Q57741270 | ||
Recommendations for Improved Standardization of Immunohistochemistry | Q58376162 | ||
Genetic Interactions in Cancer Progression and Treatment | Q63383811 | ||
NCI-MATCH pairs tumor mutations with matching drugs | Q85852392 | ||
Advanced Companion Diagnostics Facilities: Opportunity Favors the Prepared Laboratory | Q86297542 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | immunohistochemistry | Q899285 |
biomarker | Q864574 | ||
P304 | page(s) | 521-531 | |
P577 | publication date | 2017-08-24 | |
P1433 | published in | Clinical Cancer Research | Q332253 |
P1476 | title | Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial | |
P478 | volume | 24 |
Q90024930 | Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q |
Q92381135 | Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update |
Q57100413 | Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience |
Q98733440 | Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features |
Q89163281 | Molecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approach |
Q58594810 | Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria |
Q64905628 | Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. |
Q64996202 | PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. |
Q59330598 | Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution |
Search more.